Notably, in people with T2D and cardiovascular disease (CVD), a combination of glucagon-like peptide-1 receptor agonists (GLP-1 RA), sodium-glucose cotransporter-2 inhibitors (SGLT2-i), antithrombotic, antihypertensive, and lipid-lowering medications has been shown to improve major CV adverse events (MACE) [8, 12–26]. Here, SLC5A2 is linked to type 2 diabetes mellitus.